The Department of Health and Human Services, through the U.S. Food and Drug Administration (FDA), has released a Notice of Funding Opportunity (NOFO) aimed at supporting clinical trials for orphan products targeting rare diseases. This initiative seeks to address unmet medical needs by evaluating safety and efficacy for new indications in various phases (1, 2, or 3) of drug development. The funding opportunity encourages innovation and collaboration among stakeholders by supporting novel trial designs and patient engagement. Applications are invited from a diverse range of organizations and must adhere to specific submission guidelines, including a detailed budget and compliance with regulatory requirements. Key deadlines include application due dates in October 2025, 2026, and 2027, with funding contingent upon congressional appropriations. Eligible costs can reach up to $900,000 per year with supplementary funding available for innovative designs. Critically, the document outlines rigorous application and review processes, emphasizing the need for sound research rationale, study design, and engagement with patients or caregivers. The FDA aims to expedite drug development through this funding, facilitating a positive impact on the rare disease field and improving treatment options for impacted populations. Overall, this NOFO underscores the FDA's commitment to enhancing the drug approval process for rare diseases via targeted funding mechanisms.